Dovobet® (Calcipotriol and Betamethasone Dipropionate) - A - Detailing from Skin Therapy Letter


Dovobet® (Calcipotriol and Betamethasone Dipropionate)







  • Dovobet (50 micrograms/gram calcipotriol and 0.5 milligrams/gram betamethasone dipropionate) is a topical ointment approved for use in Canada to treat plaque psoriasis.
  • Dovobet has become the topical therapy of choice for many patients with plaque type psoriasis not involving the face or skin folds

There are limitations for regulators, pharmaceutical companies and pharmaceutical sales representatives to present clinical evidence following development of product monograph and drug approval. The product monograph is the starting point for this A-Detail™. It also contains evidence-based decision making processes, current standards of practice and clinical experience to provide a practical approach to the treatment of this condition.

Disclaimer: This A-Detail™ is meant to be a practical guide and does not necessarily reflect all risks, side-effects or situations associated with this product.

Next:   Clinical Exerience